In contrast to our previous study of CAR30 T-cell therapy [5], the peak of IL-6 and serum ferritin levels during CRS were slightly lower in patients treated with ASCT in tandem with CAR30 T-cell infusion, while the expansion of CAR-T cells was no significant difference, although further large-scale validation in double-arm clinical trials is warranted. The gene discussed is IL6; the disease is congenital rubella syndrome.